Received Apr 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | HR4RB | — |
11-year-old patient received an adult dose of Havrix this morning; 11-year-old patient received an adult dose of Havrix this morning; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult product administered to child in a 11-year-old male patient who received HAV (Havrix 1440 adult) (batch number HR4RB, expiry date 18-DEC-2025) for prophylaxis. On 31-MAR-2025, the patient received the 1st dose of Havrix 1440 adult. On 31-MAR-2025, an unknown time after receiving Havrix 1440 adult, the patient experienced adult product administered to child (Verbatim: 11-year-old patient received an adult dose of Havrix this morning) and overdose (Verbatim: 11-year-old patient received an adult dose of Havrix this morning). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 31-MAR-2025 Other Health Professional stated an 11-year-old patient received an adult dose of Havrix this morning, which led to Adult product administered to child and overdose. It was the first dose for the patient. The reporter consented to follow up. The Vaccine Administration Facility is the same as Primary Reporter.